2026 CAR/CSAR Practice Guideline: Retroperitoneal Sarcoma
CAR:Chinese Association for Sarcoma;CSAR:Chinese Sarcoma Academic Research Group 适用范围:成人原发性腹膜后肉瘤(RPS);不含腹膜转移癌、生殖细胞肿瘤、淋巴瘤、良性腹膜后间叶源性肿瘤;涵盖多学科评估、手术、放疗、系统治疗、复发 / 转移、随访、病理与分子检测。 Core principle: Multidisciplinary team (MDT) management is mandatory for all retroperitoneal sarcoma patients. Complete resection with negative margins remains the cornerstone of curative-intent treatment.
Preface
Retroperitoneal sarcoma (RPS) is a heterogeneous group of rare mesenchymal malignancies, characterized by deep anatomical location, large tumor size at diagnosis, proximity to vital organs and major vessels, high local recurrence rate, and distinct histotype-dependent biological behavior. The most common subtypes include well-differentiated/dedifferentiated liposarcoma (WDLS/DDLS), leiomyosarcoma (LMS), solitary fibrous tumor (SFT), and malignant peripheral nerve sheath tumor (MPNST).
Due to rarity and complexity, management decisions cannot rely solely on single-discipline judgment. This guideline is developed by the Chinese Association for Sarcoma (CAR) and Chinese Sarcoma Academic Research Group (CSAR), integrating domestic real-world data and international evidence, to standardize staging, pathological evaluation, surgical strategy, radiotherapy, systemic therapy, surveillance, and clinical trial referral.
1. Initial Evaluation and Staging
1.1 Baseline assessment
-
History and physical examination: Abdominal pain, distension, weight loss, lower limb edema, neurological symptoms, prior radiation or surgery history.
-
Imaging
-
Contrast-enhanced abdominal-pelvic CT (arterial + venous phase): first-line for diagnosis and surgical planning; evaluate tumor boundary, adjacent organ/vessel invasion, regional lymph nodes, distant metastases.
-
MRI: preferred for soft tissue contrast, neural plexus, pelvic sidewall and vascular involvement; indicated for lipomatous tumors, nerve sheath tumors.
-
Chest CT: mandatory for staging to rule out pulmonary metastases.
-
Functional imaging: ¹⁸F-FDG PET-CT is not routine. Recommended for high-grade histotypes, suspected dedifferentiation, unclear distant spread, or biopsy target selection.
-
Biopsy
-
Core needle biopsy (CNB) is strongly recommended before any planned neoadjuvant therapy or non-surgical management.
-
Avoid transperitoneal biopsy trajectory when feasible; prefer posterior transmuscular approach under CT guidance.
-
Frozen biopsy alone is insufficient for definitive subtype diagnosis and grading.
-
Laboratory tests: Routine blood, liver/kidney function, lactate dehydrogenase (LDH). No specific serum tumor marker for RPS.
1.2 Histopathology and molecular testing
-
Mandatory histologic grading: FNCLCC grading system.
-
Required immunohistochemistry according to morphology: MDM2, CDK4, STAT6, SMA, desmin, H-caldesmon, S100, SOX10, Ki-67.
-
Molecular testing recommendations:
-
WDLS/DDLS: MDM2 amplification (FISH is gold standard).
-
SFT: NAB2-STAT6 fusion.
-
Suspected MPNST: NF1 evaluation.
-
High-grade, metastatic, or refractory RPS: NGS panel (SNV, indel, CNV, fusion, TMB, MSI) for target screening and clinical trial matching.
-
MSI-H/dMMR testing for all high-grade sarcomas, as immune checkpoint inhibitor may be considered.
1.3 Staging system
Adopt AJCC/UICC soft tissue sarcoma staging (8th edition), with special note:
-
For RPS, T stage is defined by size and depth; all retroperitoneal sarcomas are deep.
-
Lymph node metastasis is rare except for epithelioid sarcoma, angiosarcoma and rhabdomyosarcoma.
-
Histotype and grade are stronger prognostic factors than T stage for WDLS/DDLS.
2. Primary localized retroperitoneal sarcoma
2.1 General surgical principle
The goal of curative surgery is macroscopically complete resection with negative margin (R0 whenever possible). En bloc resection of involved adjacent organs is often required; intentional multivisceral resection is acceptable if it achieves negative margins.
-
R1 resection (microscopic residual): local recurrence risk remains high; MDT discussion for adjuvant radiotherapy.
-
R2 resection (macroscopic residual): generally not considered curative; avoid debulking surgery without clear palliative benefit.
-
Vascular involvement: Reconstruction of inferior vena cava, iliac vessels, renal vessels may be performed in specialized centers.
-
Lymphadenectomy is not routine: only perform when imaging or biopsy confirms nodal involvement.
2.2 Histotype-specific surgical strategy
-
WDLS: Indolent, low metastatic risk; local recurrence is the main threat. Aggressive en bloc resection is indicated despite low grade.
-
DDLS: High local recurrence risk and metastatic potential; wide resection is critical.
-
LMS: Higher distant metastasis risk (lung, liver); careful systemic staging.
-
SFT: Behavior varies; high mitotic index (>10/10 HPF) and necrosis predict aggressive course.
2.3 Neoadjuvant therapy
Indications: Large tumor, borderline resectable, high-grade histology, expected close/positive margin.
-
Neoadjuvant radiotherapy: Preferred for high-grade RPS in many centers; dose 45–50 Gy, conventional fractionation. IMRT/IGRT is required to reduce bowel dose.
-
Neoadjuvant chemotherapy: Not standard for WDLS/DDLS. May be considered for high-grade LMS, MPNST, or other high-risk subtypes in MDT discussion.
-
Neoadjuvant targeted therapy: Investigational; only within clinical trials.
2.4 Adjuvant therapy
-
Adjuvant radiotherapy
-
Recommended for high-grade, R1 resection, close margin, high-risk DDLS/LMS.
-
Not routinely recommended for completely resected low-grade WDLS.
-
Timing: Usually 4–8 weeks after surgery once wound healing is satisfactory.
-
Adjuvant chemotherapy
-
Not routine for WDLS/DDLS.
-
May be offered for selected high-grade, large, deep, high-risk LMS or MPNST after MDT review. Regimen: doxorubicin + ifosfamide is the standard backbone.
3. Locally recurrent retroperitoneal sarcoma
-
Re-staging with cross-sectional imaging and chest CT; repeat biopsy is recommended if histotype/grade is uncertain or dedifferentiation is suspected.
-
If resectable: Reoperation is the preferred curative option. Prior radiotherapy limits re-irradiation feasibility.
-
If unresectable local recurrence: Systemic therapy, palliative radiotherapy, or ablation may be considered for symptom control.
-
Multiple repeated local recurrences of WDLS: Balance surgical benefit against cumulative morbidity of multivisceral resection.
4. Metastatic retroperitoneal sarcoma
4.1 First-line systemic therapy
-
Anthracycline-based regimen (doxorubicin ± ifosfamide): standard for high-grade sarcoma fit for intensive chemotherapy.
-
Single-agent doxorubicin: for patients unfit for combination.
-
Trabectedin: for LMS and WDLS/DDLS after anthracycline failure.
-
Eribulin: for LMS.
-
Pazopanib: multi-tyrosine kinase inhibitor for advanced non-adipocytic sarcoma.
-
For SFT with progressive disease: sunitinib or pazopanib can be considered.
-
MSI-H/dMMR metastatic sarcoma: PD-1 inhibitor monotherapy is recommended.
-
NTRK fusion-positive cases: TRK inhibitor.
4.2 Local ablative therapy for oligometastases
Surgical metastasectomy, SBRT, RFA may be considered for isolated pulmonary or liver oligometastases, after MDT evaluation and good systemic disease control.
4.3 Palliative care
Focus on pain, gastrointestinal obstruction, venous compression, renal function protection.
5. Radiotherapy technical notes
-
IMRT, VMAT, IGRT are preferred over 3D-CRT for retroperitoneal targets to spare small bowel, kidneys, liver, spinal cord.
-
Organ at risk constraints: small bowel, bilateral kidneys, spinal cord must be strictly limited.
-
Re-irradiation: High risk of bowel toxicity; only selected cases in specialized sarcoma centers.
-
Intraoperative radiotherapy (IORT): can be an option for selected close-margin cases in experienced centers.
6. Surveillance after curative resection
Stratified by histotype and grade:
-
WDLS: Abdominal/pelvic CT every 6 months for 5 years, then annually. Chest CT annually.
-
DDLS / LMS / MPNST: Abdominal/pelvic CT + chest CT every 3–4 months for first 2 years, every 6 months for years 3–5, annually thereafter.
-
SFT: Surveillance according to mitotic index and risk stratification; indolent low-risk SFT may use longer intervals.
-
Patient education: Early report of abdominal distension, pain, lower limb swelling.
7. Special scenarios
-
Bilateral renal involvement: Preoperative renal function planning, unilateral nephrectomy, autotransplantation, or nephron-sparing surgery in specialized centers.
-
Venal cava invasion: Tumor thrombus requires vascular surgery collaboration.
-
Synchronous metastatic disease at presentation: Systemic therapy first; local resection only for symptomatic primary or oligometastatic disease.
-
Pediatric-type RPS: Refer to pediatric sarcoma guidelines.
8. MDT requirement
All RPS patients should be discussed at sarcoma MDT, including sarcoma surgeon, radiation oncologist, medical oncologist, radiologist, pathologist, interventional radiologist, and supportive care team. Complex cases should be centralized to high-volume sarcoma centers.
9. Summary
Retroperitoneal sarcoma is a heterogeneous disease; histotype and grade dominate prognosis. Complete surgical resection with negative margins is the mainstay of curative treatment. Neoadjuvant/adjuvant radiotherapy is selectively used for high-risk localized disease. Chemotherapy benefit is limited for WDLS/DDLS, while anthracycline-based chemotherapy remains the backbone for high-grade advanced sarcoma. Recurrent and metastatic disease requires individualized MDT decision-making, including surgery, radiotherapy, targeted agents and immunotherapy when actionable biomarkers are identified.
Citation
Chinese Association for Sarcoma (CAR), Chinese Sarcoma Academic Research Group (CSAR). 2026 CAR/CSAR Practice Guideline: Retroperitoneal Sarcoma. Chinese Journal of Sarcoma and Bone Tumor, 2026, 15(3):131–148